Evidence map›Paper›PMID 41079483›Full record

ReviewFrontiers in neuroscience2025

Graph neural networks in Alzheimer's disease diagnosis: a review of unimodal and multimodal advances.

Shahzad Ali, Michele Piana, Matteo Pardini, Sara Garbarino

Abstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shahzad AliDepartment of Pharmacy and Biotechnology, Alma Mater Studiorum - Universitá di Bologna, Bologna, Italy.
Michele PianaLife Science Computational Laboratory (LISCOMP), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, Italy.
Matteo PardiniDipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Università degli Studi di Genova, Genova, Italy.
Sara GarbarinoLife Science Computational Laboratory (LISCOMP), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's Disease (AD), a leading neurodegenerative disorder, presents significant global health challenges. Advances in graph neural networks (GNNs) offer promising tools for analyzing multimodal neuroimaging data to improve AD diagnosis. This review provides a comprehensive overview of GNN applications in AD diagnosis, focusing on data sources, modalities, sample sizes, classification tasks, and diagnostic performance. Drawing on extensive literature searches across PubMed, IEEE Xplorer, Scopus, and Springer, we analyze key GNN frameworks and critically evaluate their limitations, challenges, and opportunities for improvement. In addition, we present a comparative analysis to evaluate the generalizability and robustness of GNN methods across different datasets, such as ADNI, OASIS, TADPOLE, UK Biobank, in-house, etc. Furthermore, we provide a critical methodological comparison across families of GNN architectures (i.e., GCN, ChebNet, GraphSAGE, GAT, GIN, etc.) in the context of AD. Finally, we outline future research directions to refine GNN-based diagnostic methods and highlight their potential role in advancing AI-driven neuroimaging solutions. Our findings aim to foster the integration of AI technologies in neurodegenerative disease research and clinical practice.

Indexed as

Alzheimer's diseasedeep learningdiagnosisgraph neural networkmultimodalneuroimagingneurological disordersreview

Identifiers

PMID41079483
PMCPMC12511118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.